Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy in Richter Syndrome

Cancer

Volumn 100, Issue 10, 2004, Pages 2195-2200

  Tsimberidou, Apostolia Maria ^a   Murray, James L ^a   O'Brien, Susan ^a   Wierda, William G ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

90Y Ibritumomab tiuxetan; Hematologic toxicity; Radioimmunotherapy; Richter syndrome

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; NITROSOUREA; PREDNISONE; RITUXIMAB; VINCRISTINE; YTTRIUM 90;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHOMA; MALE; NEUTROPENIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; RICHTER SYNDROME; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE MARROW; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 2342648074     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20252     Document Type: Article

References (31)

1. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol. 1993;11:1985-1989.
2. Dabaja BS, O'Brien SM, Kantarjian HM, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome. Leuk Lymphoma. 2001;42:329-337.
3. Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97:1711-1720.
4. Tsimberidou AM, O'Brien SM, Cortes JE, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002;43:767-772.
5. Harousseau JL, Flandrin G, Tricot G, Brouet JC, Seligmann M, Bernard J. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: a study of 25 cases. Cancer. 1981;48:1302-1308.
6. Multani P. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Int J Hematol. 2002;76:401-410.
7. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology (Am Soc Hematol Educ Program). 2002; (1):241-262.
8. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391-398.
9. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002;20:3545-3557.
10. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002;29(1 Suppl. 2):87-92.
11. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol/Hematol. 2001;39(1-2):195-201.
12. White CA, Berlfein JR, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2000;1:303-312.
13. Witzig TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Semin Oncol. 2000;27(6 Suppl. 12):74-78.
14. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5(10 Suppl.):3281s-3286s.
15. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Ann Rev Med. 2001;52:125-145.
16. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol/Hematol. 2001;39(1-2):181-194.
17. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
18. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11:375-380.
19. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
20. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
21. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
22. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002;99:4336-4342.
23. Winter JN, Inwards D, Erwin W, et al. Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-Cell NHL [abstract]. Blood 2001;98:2835a.
24. Grillo-Lopez AJ, Chinn P, Morena R, Varns C, Parker E, Soligner AM. Phase I study of IDEC-Y2B8: 90-Yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma [abstract]. Blood. 1995;86:55a.
25. Crawford LM Jr. From the Food and Drug Administration. JAMA. 2002;287:1640.
26. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
27. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia-long term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003;44:1719-1725.
29. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
30. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507-2513.
31. O'Brien SM, Wierda W, Geisler D, Lerner S, Albitar M, Keating M. Yttrium-90 ibritumomab tiuxetan for minimal residual disesase in CLL [abstract]. Proc Am Soc Clin Oncol. 2003;22:579.